Detail akcie Summit Therap Rg online

Business Summary: Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Summit Therapeutics Inc revenues was not reported. Net loss increased from $103.9M to $628.6M. Higher net loss reflects C difficile infection CDIprogram and antibiotic pipeline res segment loss increase from $102M to $635.3M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.15 to -$0.85.